Diabetes Technology Updates: Revolutionizing Care in 2025

Diabetes care is undergoing a remarkable transformation, thanks to rapid advancements in technology. From next-generation insulin pumps and continuous glucose monitors to the integration of artificial intelligence and implantable sensors, the tools available in 2025 are more sophisticated and more accessible than ever before. Here, we'll go over some of the most notable diabetes technology updates from recent conferences.

Diabetes-Related Technology Updates from ATTD 2025

The 18th annual International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) was held in Amsterdam from March 19 to 22, 2025. During this conference, many groundbreaking diabetes advancements were announced. From cutting-edge research on continuous glucose monitoring and automated insulin delivery to future technological rollouts, there are several ways that diabetes tech is paving the way to simplified care and longevity.

Dexcom's 15-Day CGM and the State of Type 2 Report

During the ATTD, Dexcom announced updates on enhanced continuous glucose monitors alongside new insulin delivery integrations. The accuracy of the Dexcom G7 iCGM was compared to laboratory-standard analysis during a clinical trial, with key metrics including the mean absolute relative difference (MARD) and percentage agreement with predefined glucose ranges. The results showed that the G7 iCGM had an overall MARD of 8.0% with 87.7% of sensor readings falling within 15 mg/dL or 15% reference values. This meets and exceeds regulatory performance benchmarks for these types of systems.

Simply put, the 15-day Dexcom G7 CGM's updated technology is accurate and effective, with no signs of serious adverse effects. This extended use of CGMs can help people with diabetes accurately track blood glucose levels in real-time with fewer interruptions to their day, which can help simplify overall management.

During the conference, Dexcom also revealed its "State of Type 2 Report: Access and Attitudes Across Europe and the Middle East." Within the report, the findings provide insights about diabetes management and perceptions of technology across people with type 2 diabetes and healthcare professionals in various countries. Notable findings include:

• 52% of healthcare providers ranked access to CGM and education as the ideal way to help people with type 2 diabetes manage the condition in the next 10 years.
• 93% of people with type 2 diabetes who have used a CGM agreed that it had a positive impact.
• 96% of healthcare providers see CGMs as the standard of care, especially for those who rely on multiple daily insulin injections.

Omnipod® 5 Automated Insulin Delivery (AID) System

People with type 1 diabetes are often faced with the challenge of having to administer multiple daily injections (MDI), which can hinder glucose control if not done correctly or without careful monitoring.

Insulet’s tubeless Omnipod® 5 is an automated insulin delivery (AID) system that has recently received FDA approval. However, in the past, the benefits of AID systems over MDI were not fully clear or established. During the 2025 ATTD, results from the RADIANT study finally provided some clarification.

The study involved adults and children with type 1 diabetes who had been using an Abbott FreeStyle Libre continuous glucose monitor to deliver multiple daily injections for at least three months. After a collection period, participants were randomly assigned to either switch to the Omnipod® 5 or continue with MDI. The key measurements during this time were HbA1c.

Results showed a significant improvement in blood sugar levels and overall control for the individuals using automated insulin delivery. On average, HbA1c levels dropped from 8.1% to 7.2% in three months, while the time in range for target glucose levels increased from 39% to 65% without an increase in hypoglycemia.

Control IQ+ AID

During the ATTD conference, Tandem Diabetes Care, Inc. presented their recent findings from the 2IQP study, which evaluated the role of automated insulin delivery systems in adults who use insulin to treat type 2 diabetes. This is an innovation in diabetes research, as most AID systems have only been studied in individuals with type 2 diabetes.

During the study, both groups used continuous glucose monitoring, but half were assigned an AID system and the other half were told to continue their regular insulin administration technique. Results showed that those using the automated insulin pump with Control-IQ technology had a greater improvement in blood sugar control throughout the trial, with A1c levels dropping by 0.9% (compared to 0.3% in the control group). Those using the AID system also spent more time in the target glucose range (64% vs. 48%).

Insulin Patch Pumps

New insulin patch pumps like Niia Signature are also being rolled out for purchase. This is a small device that pumps insulin and measures glucose in one unit. The technology combines the simplicity of a pen and the glucose control of a pump in one device to help make diabetes management easier. Its ability to be controlled via smartphone also allows individuals more options and greater access to data throughout the day.

Medtronic Smart Insulin Pen Systems

Medtronic also released a smart insulin pen system, called the InPen. It's a reusable smart insulin pen that uses Bluetooth® technology to send dose information to a mobile app, reducing the mental math required for diabetes management. You can learn more about it here.

Advanced Artificial Pancreas Systems

Another interesting update in diabetes tech news was the announcement of an advanced artificial pancreas system being tested. The Inreda bihormonal artificial pancreas is currently in research and testing to help deliver both insulin and glucagon to reduce instances of high and low blood sugar events. It's a fully closed-loop insulin delivery system, meaning that it doesn't require any help from the wearer (compared to hybrid closed-loop systems). When paired with a CGM, insulin doses and glucagon can be automatically administered based on readings in real-time.

So far, research has been promising, showing an 80% average time in the target glucose range compared to 60% in regular pump therapy. However, since the system requires two CGM sensors and two infusion sets (one for insulin and one for glucagon), it's unclear whether individuals will prefer this over hybrid systems.

Diabetes Driving Pal

Another potential update for the future of diabetes care discussed during the conference is an app called Diabetes Driving Pal. This is an app that was created to help address the challenges that driving with diabetes can bring, especially during periods of low blood sugar. It's a hands-free app with a goal of preventing hypoglycemia-related accidents by providing real-time monitoring and voice-based safety alerts to help drivers. Although it hasn't launched yet, the creators are working to make this technology easy to use and as helpful as possible. They're even working to code the app so that it can alert a driver to a future low blood sugar event and suggest a nearby coffee shop or restaurant for fast-acting carbohydrates.

Diabetes-Related Technology Updates from ADA 2025

The American Diabetes Association's 2025 scientific conference also just came to an end, where even more future developments were announced. Some of the most notable from this conference include:

Semaglutide (Ozempic/Wegovy) Combined with AID Therapy

• In a 6-month study, people with type 1 diabetes using AID and semaglutide:
• Lost an average of 18 pounds.
• Increased time in range (70–180 mg/dL).
• Reduced time spent below range, with no rise in hypoglycemia or DKA.

Sequel’s Twiist AID System (Launch: July 7, 2025)

• This is a new AID system powered by Tidepool Loop that uses a circular, tubed pump with sound-wave-based insulin measurement for better dosing accuracy and faster occlusion detection.

Beta Bionics Mint Patch Pump (Coming 2027):

• This tubeless patch pump with a 3-day wear time and a 200-unit insulin reservoir is expected to launch in 2027. Its embedded AI algorithm means that there's no smartphone or Bluetooth pairing required.

Implantable Glucotrack Sensor (Expected 2028):

• This next-generation glucose monitoring system is designed to eliminate CGM lag (usually about 5 to 6 minutes). It's implanted under the skin and measures glucose directly from the bloodstream instead of using interstitial fluid. Long-term clinical trials are currently being planned.

How Artificial Intelligence Can Impact Diabetes Care

Finally, diabetes care has also been recently driven by the rapid integration of artificial intelligence (AI). Through machine learning algorithms, AI can analyze vast amounts of data from CGMs, insulin pumps, food logs, and activity trackers to identify patterns and predict blood sugar trends. This can greatly complement current diabetes care management techniques.

As technology advances, AI-driven systems have the potential to reduce daily diabetes management and improve outcomes by helping both patients and healthcare providers make smarter, data-informed decisions. You can read more about the impact of AI on diabetes care in 2025 here.

As the diabetes technology landscape continues to evolve, the future holds great promise for improving quality of life, reducing complications, and making care more seamless for people of all ages. To help ensure you have everything you need to manage diabetes today, Byram Healthcare carries a wide range of high-quality diabetes products from leading manufacturers.